scholarly journals Adipokines and Systemic Rheumatic Diseases: Linking Inflammation, Immunity and Metabolism

10.5772/25979 ◽  
2012 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Veronica Lopez ◽  
Rodolfo Gomez ◽  
Francisca Lago ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Systemic Rheumatic Diseases

Re-evaluation of the Anti-streptolysin O Test for Systemic Rheumatic Diseases

2011 ◽  
Vol 1 (3) ◽  
pp. 153
Author(s):  
Kyoung Soo Shin ◽  
La-He Jearn ◽  
Think-You Kim
Keyword(s):  
Rheumatic Diseases ◽  
Streptolysin O ◽  
Systemic Rheumatic Diseases

scholarly journals POS1155 INFECTIOUS RISK DURING BIOLOGIC THERAPY FOR INFLAMMATORY RHEUMATIC DISEASES: DATA FROM THE TUNISIAN BINAR REGISTRY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 856.2-856
Author(s):  
S. Boussaid ◽  
R. Ben Aissa ◽  
S. Kochbati ◽  
M. Elleuch ◽  
L. Abdelmoula ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Infectious Agent ◽  
National Registry ◽  
Inflammatory Rheumatic Diseases ◽  
Infection Frequency ◽  
Necrosis Factor Alpha ◽  
Infectious Episode ◽  
Infectious Risk ◽  
Systemic Rheumatic Diseases ◽  
Factor Alpha

Background:The development of biologics for the treatment of systemic rheumatic diseases increased the risk of infections. The management of this complication deserves particular attention since it remains a major cause of morbidity and mortality.Objectives:The aim of our study was to determine infection frequency under biological treatment and consequences on the therapeutic management.Methods:Patients included in the Biological National Registry (BINAR) from 2016 to 2020. Data related to the disease, biological agents, and infections occurring under biologic disease-modifying antirheumatic drugs (bDMARDs) were collected.Results:The study included 298 patients with a mean age of 49.2 years [18-79] 175 patients with rheumatoid arthritis and 123 with spondyloarthritis (Axial Spondyloarthritis=48, Enteropathic Arthritis=41, Psoriatic Arthritis=34). Anti Tumor necrosis factor-alpha (Anti-TNF) agents were the most prescribed bDMARDs in 87.9% (n=263) of patients: Infliximab 20.4% (n=61),Etanercept 23.1%(n=69), Adalimumab 24.6%(n=74) and Certolizumab (n=79). No patients were treated with Golimumab. Tocilizumab and Rituximab were prescribed respectively in 10.4% (n=31) and 5% (n=15) of patients. Infections occured in 9 patients (3.1%) with a total of 13 infectious episodes 12 bacterial and a viral one. The site of infections was: respiratory (38%), urinary (15%), cutaneous (23%), ORL (8%), infective endocarditis (8%), and other (8%). The infectious agent was identified in only 3 patients. The outcomes were favorable in most cases except in one patient where there was a definitive interruption of bDMARDs. The patient was hospitalized for sepsis complicating a cutaneous infection with favorable outcomes under antibiotics within a week. The biological agent with higher risk of infections was Tocilizumab (p = 0.056), unlike Rituximab (p = 0.483) and Anti-TNF (p = 0.082). All patients who had an infectious episode were under corticosteroids.Conclusion:Our results confirm that bDMARDs are predisposing to infections, but data from BINAR showed that most infections were trivial with no serious outcomes. Therefore, infections should be assessed in patients under bDMARDs for an early therapeutic intervention.Disclosure of Interests:None declared.

Outcome of Patients With Systemic Rheumatic Diseases Admitted to a Medical Intensive Care Unit

2010 ◽  
Vol 16 (8) ◽  
pp. 400-402 ◽  
Author(s):  
Javier A. Cavallasca ◽  
María del Rosario Maliandi ◽  
Sergio Sarquis ◽  
Maria Betina Nishishinya ◽  
Alejandra Schvartz ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Rheumatic Diseases ◽  
Medical Intensive Care Unit ◽  
Systemic Rheumatic Diseases ◽  
Medical Intensive Care

scholarly journals The PTPN22 R620W polymorphism is not associated with systemic rheumatic diseases in South Africans

Rheumatology ◽  
2009 ◽  
Vol 49 (4) ◽  
pp. 820-821 ◽  
Author(s):  
M. Tikly ◽  
N. Govind ◽  
J. Frost ◽  
M. Ramsay
Keyword(s):  
Rheumatic Diseases ◽  
South Africans ◽  
Systemic Rheumatic Diseases

scholarly journals Pharmacotherapy in Systemic Rheumatic Diseases

2021 ◽  
pp. 83-104
Author(s):  
Layla Borham ◽  
Waleed Hafiz
Keyword(s):  
Rheumatic Diseases ◽  
Systemic Rheumatic Diseases

AbstractBy the end of this chapter, you should be able to:

Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases

2020 ◽  
Author(s):  
Min Jung Kim ◽  
Eun Bong Lee ◽  
Yeong Wook Song ◽  
Jin Kyun Park
Keyword(s):  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Inflammatory Markers ◽  
Acute Phase Proteins ◽  
Acute Infection ◽  
Inflammatory Myopathy ◽  
University Hospital ◽  
Treatment Naïve ◽  
Systemic Rheumatic Diseases ◽  
Wbc Count

Abstract Background The host inflammatory response against infection is characterized by leukocytosis, and the release of cytokines and acute phase proteins. However, routine inflammatory markers are not always elevated in systemic rheumatic diseases (SRD). Here, we aimed to systematically evaluate and compare the clinical implications of common inflammatory markers in systemic rheumatic diseases (SRDs). Methods We investigated the profiles of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell (WBC) count in treatment-naïve patients with SRDs, osteoarthritis and pneumonia diagnosed at Seoul National University Hospital during 2004-2016. SRDs included rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and adult onset of Still disease (AOSD). Associations between inflammatory markers were evaluated using Pearson’s correlation and regression analysis. Differences between correlations were compared using Steiger’s z-test. Receiver operating characteristic (ROC) curve analysis was performed to examine the predictive value of inflammatory markers for SRD diagnosis. Results We identified 1191 patients with SRDs, osteoarthritis and pneumonia. Leukocytosis was present in <15% SRD patients. There was marked variability in ESR and CRP levels among different SRDs. The highest mean CRP levels (mean ± SD, mg/dL) were observed in those with AOSD (11.3±7.9), followed by RA (2.0±3.3), IIM (1.8±3.5), SLE (1.5±3.1), SSc (0.6±1.3) and AS (0.08±0.1). Mean ESR (mm/hr) was also highest in AOSD (71.2±31.0), followed by SLE (47.3±34.2), RA (45.5±30.6), IIM (40.8±24.8) and SSc (27.8±26.0). All SRDs showed significant positive correlations between ESR and CRP: greatest in RA (r=0.53, p<0.001) and weakest in SLE (r=0.20, p=0.03). WBC correlated weakly with CRP but not with ESR in most SRDs. While the AUC for WBC count (0.54-0.68) was less than that of ESR or CRP, the AUC for ESR and CRP (0.69-0.86) were similar in SRD. The optimal cuff-off values for inflammatory markers predicting SRD were within or slightly above the normal limit. Conclusions Unlike acute infection, ESR, CRP and WBC count are not always elevated in treatment-naïve patients with SRD. Thus, common inflammatory markers have limited value for diagnosis and assessment of disease activity of SRD.

Sign in / Sign up

Export Citation Format

Share Document